Pantoprazol Oresund Pharma (Pantoprazole)

Pantoprazol Oresund Pharma is a proton pump inhibitor that acts on the gastric acid secretion pathway.

• Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the esophageal lining.
• Erosive gastritis and duodenal ulcers: accelerates ulcer healing by maintaining a higher gastric pH.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with this rare neuroendocrine tumor.

• Pantoprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the parietal cell surface, blocking the final step of acid secretion. This results in a sustained reduction of gastric acidity, allowing mucosal healing and symptom control.

Pantoprazol Oresund Pharma may cause adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: usually transient.
• Nausea or abdominal discomfort.
• Flatulence or bloating.
• Constipation.
• Dry mouth.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing.
• Clostridioides difficile‑associated colitis.
• Low magnesium levels (hypomagnesemia) with prolonged use.
• Acute interstitial nephritis.
• Bone fractures with long‑term therapy.
• Liver enzyme elevations.

Before starting Pantoprazol Oresund Pharma, consider the following safety measures:

• Assess renal function: dose adjustment may be required in severe impairment.
• Review concomitant medications: potential for reduced efficacy of drugs needing acidic pH.
• Monitor long‑term users: watch for magnesium deficiency and bone health.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation.
• Elderly patients: start at the lowest effective dose and monitor for adverse effects.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazole can affect the absorption and metabolism of several medicines. Review patient medication lists carefully.

Major Interactions (Avoid)

• Antiretroviral protease inhibitors (e.g., atazanavir, nelfinavir): markedly reduced plasma concentrations.
• Certain antifungal agents (e.g., itraconazole, ketoconazole): decreased absorption and efficacy.
• Clopidogrel: reduced conversion to its active metabolite, diminishing antiplatelet effect.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR; monitor coagulation parameters.
• Methotrexate: reduced renal clearance may raise serum levels.
• Digoxin: slight increase in serum concentration; observe for toxicity signs.